Abstract: The present disclosure provides an assay device and associated method(s) to facilitate the determination of risk of a subject to develop severe forms of SARS-CoV2 infection. Said determination of risk or genetic predisposition to severe forms of SARS-CoV2 infection employing the assay device and associated method(s) relies on specifically designed CRISPR-Cas system(s). Said CRISPR-Cas system(s) employed in the present disclosure are further characterized by unique guide sequences that enable detection of presence or absence of specific Single Nucleotide Polymorphisms (SNPs) in a sample, wherein the SNPs have a genetic correlation with severe forms of SARS-CoV2 infection.

Abstract: A support vector machine (110) is used to predict who, among a population of patients with diabetes mellitus, will develop proteinuria which is in indicator of diabetic nephropathy. The support vector machine (110) is trained using test results of the patients from blood biochemistry and haemotology tests. The training and testing of the support vector machine (110) used data in which the entire patient population did not exhibit signs of proteinuria at a predetermined time period and three months later, and some of the patient population had proteinuria six months from the predetermined time period. The support vector machine (110) is used to predict who, among patients with diabetes mellitus using lest results from a predetermined time period and three months later, will develop proteinuria at six months from the predetermined time period. The input data to the support vector machine (110) included different parameters of test results at a predetermined time and three months later.